Fierce Healthcare April 13, 2021
As growing numbers of specialty drugs come through the development pipeline, employers are finding new strategies to manage the associated costs, a new report from Willis Towers Watson shows.
Katie Asch, senior director and U.S. consulting pharmacy practice lead at WTW, told Fierce Healthcare that two-thirds of new drug approvals are for specialty drug products. In addition, these products are gaining approval for additional indications, Asch said.
For example, Sanofi’s Dupixent was launched as a drug to treat eczema but has since been approved for asthma, she said.
“We’re also seeing an expansion of the types of conditions and indications that existing specialty drugs can be used for,” she said.
The WTW analysis groups potential solutions in financial and clinical...
Today's Sponsors
Today's Sponsor